Author(s)

Siyuan Geng ¹, Tao Cai ¹

Affiliation(s)

¹ The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

Corresponding Author

Siyuan Geng

ABSTRACT

Chronic urticaria during pregnancy represents a prevalent dermatological condition, with some patients experiencing severe symptoms including intense pruritus, sleep disturbances, and potentially life-threatening manifestations. However, due to the unique physiological state of pregnancy, treatment options are significantly constrained. Conventional antihistamine therapy remains the primary pharmacological approach, yet exhibits suboptimal efficacy in certain cases. Prolonged glucocorticoid administration may elevate risks of gestational hypertension and preterm delivery. Omalizumab, a humanized monoclonal antibody targeting immunoglobulin E (IgE), has emerged in recent years as a potential therapeutic alternative for refractory chronic urticaria in pregnant populations. This article reviews the relevant studies on the treatment of chronic urticaria during pregnancy with omalizumab, elaborates the mechanism of action of omalizumab, analyzes the treatment needs and traditional treatment methods of chronic urticaria during pregnancy, explores the treatment of chronic urticaria during pregnancy with omalizumab, and compares the differences in safety and effectiveness between omalizumab and traditional treatments, so as to provide reference for clinical treatment. 

KEYWORDS

Omalizumab; Pregnancy; Chronic Urticaria; Safety; Efficacy

CITE THIS PAPER

Siyuan Geng, Tao Cai. Omalizumab in the Treatment of Chronic Urticaria during Pregnancy. MEDS Clinical Medicine (2025) Vol. 6: 99-104. DOI: http://dx.doi.org/10.23977/medsc.2025.060115.

REFERENCES

[1] He L, Yi W, Huang X, Long H, Lu Q. Chronic Urticaria: Advances in Understanding of the Disease and Clinical Management. Clin Rev Allergy Immunol. 2021;61(3):424-448. doi:10.1007/s12016-021-08886-x
[2] Schaefer P. Acute and Chronic Urticaria: Evaluation and Treatment. Am Fam Physician. 2017;95(11):717-724
[3] Kocatürk E, Podder I, Zenclussen AC, et al. Urticaria in Pregnancy and Lactation. Front Allergy. 2022;3:892673. Published 2022 Jul 7. doi:10.3389/falgy.2022.892673
[4] Belliveau PP. Omalizumab: a monoclonal anti-IgE antibody. MedGenMed. 2005;7(1):27. Published 2005 Jan 27.
[5] Godse K, Mehta A, Patil S, Gautam M, Nadkarni N. Omalizumab-A Review. Indian J Dermatol. 2015;60(4):381-384. doi:10.4103/0019-5154.160490
[6] Maurer M, Giménez-Arnau A, Ensina LF, Chu CY, Jaumont X, Tassinari P. Chronic urticaria treatment patterns and changes in quality of life: AWARE study 2-year results. World Allergy Organ J. 2020;13(9):100460. Published 2020 Sep 12. doi:10.1016/j.waojou.2020.100460
[7] Kocatürk E, Al-Ahmad M, Krause K, et al. Effects of pregnancy on chronic urticaria: Results of the PREG-CU UCARE study. Allergy. 2021;76(10):3133-3144. doi:10.1111/all.14950
[8] Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734-766. doi:10.1111/all.15090
[9] Kocatürk E, Al-Ahmad M, Krause K, et al. Treatment patterns and outcomes in patients with chronic urticaria during pregnancy: Results of PREG-CU, a UCARE study. J Eur Acad Dermatol Venereol. 2023;37(2):356-364. doi:10.1111/jdv.18574
[10] Hansen C, Desrosiers TA, Wisniewski K, Strickland MJ, Werler MM, Gilboa SM. Use of antihistamine medications during early pregnancy and selected birth defects: The National Birth Defects Prevention Study, 1997-2011. Birth Defects Res. 2020;112(16):1234-1252. doi:10.1002/bdr2.1749
[11] Smedts HP, de Jonge L, Bandola SJ, et al. Early pregnancy exposure to antihistamines and risk of congenital heart defects: results of two case-control studies. Eur J Epidemiol. 2014;29(9):653-661. doi:10.1007/s10654-014-9925-0
[12] Andersson NW, Poulsen HE, Andersen JT. Desloratadine Use During Pregnancy and Risk of Adverse Fetal Outcomes: A Nationwide Cohort Study. J Allergy Clin Immunol Pract. 2020;8(5):1598-1605. doi:10.1016/j.jaip.2020.02.017
[13] Etwel F, Faught LH, Rieder MJ, Koren G. The Risk of Adverse Pregnancy Outcome After First Trimester Exposure to H1 Antihistamines: A Systematic Review and Meta-Analysis. Drug Saf. 2017;40(2):121-132. doi:10.1007/s40264-016-0479-9
[14] Diav-Citrin O, Shechtman S, Aharonovich A, et al. Pregnancy outcome after gestational exposure to loratadine or antihistamines: a prospective controlled cohort study. J Allergy Clin Immunol. 2003;111(6):1239-1243. doi:10.1067/mai.2003.1499
[15] Carmichael SL, Shaw GM, Ma C, et al. Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol. 2007;197(6):585.e1-e7. doi:10.1016/j.ajog.2007.05.046
[16] Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000;62(6):385-392. doi:10.1002/1096-9926(200012)62:6<385::AID-TERA5>3.0.CO;2-Z
[17] Liao SL, Yu M, Zhao ZT, Maurer M. Case Report: Omalizumab for Chronic Spontaneous Urticaria in Pregnancy. Front Immunol. 2021;12:652973. Published 2021 Mar 16. doi:10.3389/fimmu.2021.652973
[18] Patruno C, Guarneri F, Nettis E, et al. Safety of omalizumab in chronic urticaria during pregnancy: a real-life study. Clin Exp Dermatol. 2024;49(4):344-347. doi:10.1093/ced/llad386
[19] Losappio LM, Mirone C, Schroeder JW, Scibilia J, Balossi L, Pastorello EA. Omalizumab Use in Chronic Spontaneous Urticaria during Pregnancy and a Four Years' Follow-Up: A Case Report. Case Rep Dermatol. 2020;12(3):174-177. Published 2020 Oct 8. doi:10.1159/000509179
[20] González-Medina M, Curto-Barredo L, Labrador-Horrillo M, Giménez-Arnau A. Omalizumab use during pregnancy for chronic spontaneous urticaria (CSU): report of two cases. J Eur Acad Dermatol Venereol. 2017;31(5):e245-e246. doi:10.1111/jdv.14034
[21] Ensina LF, Cusato-Ensina AP, Camelo-Nunes IC, Solé D. Omalizumab as Third-Line Therapy for Urticaria During Pregnancy. J Investig Allergol Clin Immunol. 2017;27(5):326-327. doi:10.18176/jiaci.0179
[22] Cuervo-Pardo L, Barcena-Blanch M, Radojicic C. Omalizumab use during pregnancy for CIU: a tertiary care experience. Eur Ann Allergy Clin Immunol. 2016;48(4):145-146
[23] Ghazanfar MN, Thomsen SF. Successful and Safe Treatment of Chronic Spontaneous Urticaria with Omalizumab in a Woman during Two Consecutive Pregnancies. Case Rep Med. 2015;2015:368053. doi:10.1155/2015/368053
[24] Shakuntulla F, Chiarella SE. Safety of Biologics for Atopic Diseases During Pregnancy. J Allergy Clin Immunol Pract. 2022;10(12):3149-3155. doi:10.1016/j.jaip.2022.08.013

Sponsors, Associates, and Links

---

• Journal of Neurobiology and Genetics
  
  
• Medical Imaging and Nuclear Medicine
  
  
• Bacterial Genetics and Ecology
  
  
• Transactions on Cancer
  
  
• Journal of Biophysics and Ecology
  
  
• Journal of Animal Science and Veterinary
  
  
• Academic Journal of Biochemistry and Molecular Biology
  
  
• Transactions on Cell and Developmental Biology
  
  
• Rehabilitation Engineering & Assistive Technology
  
  
• Orthopaedics and Sports Medicine
  
  
• Hematology and Stem Cell
  
  
• Journal of Intelligent Informatics and Biomedical Engineering
  
  
• MEDS Basic Medicine
  
  
• MEDS Stomatology
  
  
• MEDS Public Health and Preventive Medicine
  
  
• MEDS Chinese Medicine
  
  
• Journal of Enzyme Engineering
  
  
• Advances in Industrial Pharmacy and Pharmaceutical Sciences
  
  
• Bacteriology and Microbiology
  
  
• Advances in Physiology and Pathophysiology
  
  
• Journal of Vision and Ophthalmology
  
  
• Frontiers of Obstetrics and Gynecology
  
  
• Digestive Disease and Diabetes
  
  
• Advances in Immunology and Vaccines
  
  
• Nanomedicine and Drug Delivery
  
  
• Cardiology and Vascular System
  
  
• Pediatrics and Child Health
  
  
• Journal of Reproductive Medicine and Contraception
  
  
• Journal of Respiratory and Lung Disease
  
  
• Journal of Bioinformatics and Biomedicine